Polsinelli Podcasts - FDA Denies Amgen Citizen Petition in Biosimilar Dispute

Polsinelli
Contact
The U.S. Food and Drug Administration rejected Amgen Inc.’s request that biosimilars makers be forced to share their applications and manufacturing processes with competitors, exacerbating the company’s recent defeat in litigation with Sandoz Inc.

The FDA’s action came in response to a citizen petition in which Amgen urged regulators to require biosimilar applicants to certify that they will follow information-sharing provisions of the See more +

The U.S. Food and Drug Administration rejected Amgen Inc.’s request that biosimilars makers be forced to share their applications and manufacturing processes with competitors, exacerbating the company’s recent defeat in litigation with Sandoz Inc.

The FDA’s action came in response to a citizen petition in which Amgen urged regulators to require biosimilar applicants to certify that they will follow information-sharing provisions of the Biologics Price Competition and Innovation Act, which was part of the Affordable Care Act. In a Polsinelli Podcast, IP attorney Morgan Kirley discusses the decision and other aspects of biosimilars. To learn more about the firm's capabilities in this area, go to www.polsinelli.com

See less -

Embed
Copy

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Polsinelli | Attorney Advertising

Written by:

Polsinelli
Contact
more
less

Polsinelli on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.